Overview

Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study

Status:
NOT_YET_RECRUITING
Trial end date:
2027-03-19
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out how Zulresso®/brexanolone influences Posttraumatic Stress Disorder (PTSD) symptoms and alcohol use.
Phase:
PHASE2
Details
Lead Sponsor:
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Collaborators:
Congressionally Directed Medical Research Programs
RTI International
Sage Therapeutics
United States Department of Defense
VA Connecticut Healthcare System
Yale University
Treatments:
brexanolone